)
PureTech Health (PRTC) investor relations material
PureTech Health H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Entered 2025 with strong clinical momentum, advancing deupirfenidone (LYT-100) and launching Celea Therapeutics and Gallop Oncology, while progressing Seaport Therapeutics.
Maintained a strong financial position with $319.6M in PureTech-level cash as of June 30, 2025, providing operational runway into 2028.
Focused on three strategic pillars: advancing new treatments, strengthening UK capital market engagement, and disciplined capital allocation, including appointing new leadership and planning to add directors with UK expertise.
Refined capital allocation to prioritize value-accretive investments and potential capital returns, with operational support for Celea and Gallop transitioning to Founded Entities in 2026.
Financial highlights
Ended H1 2025 with $319.6M in cash, cash equivalents, and short-term investments, down from $366M at FY 2024.
Total revenue for H1 2025 was $1.9M, up 542% year-over-year, driven by Cobenfy (KarXT) royalty revenue.
Operating expenses for H1 2025 were $49.8M, down from $66.7M in H1 2024, reflecting Seaport deconsolidation and workforce reductions.
Net loss attributable to owners was $44.6M, compared to $41.8M in H1 2024.
Returned $150M to shareholders since 2022, including a $100M tender offer in 2024.
Outlook and guidance
Operational runway extends into 2028, with further reductions in R&D and G&A expenses expected as Gallop Oncology and Celea Therapeutics secure external funding and spin out.
Phase III trial for deupirfenidone in IPF expected to initiate in H1 2026, pending FDA alignment in Q3 2025.
Key data readouts for Gallop Oncology's LYT-200 in AML/MDS expected in Q4 2025 and H1 2026.
Vedanta’s VE303 Phase 3 topline data expected in 2026; Seaport’s Phase 2b BUOY-1 study ongoing.
Next PureTech Health earnings date
Next PureTech Health earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)